In the fall of 2015, the US Food and Drug Administration approved the addition of a novel, much-needed treatment option for patients with metastatic pancreatic cancer, a particularly hard-to-treat form of the disease, in the second-line setting following progression on gemcitabine- based chemotherapy.1 MM-398 is a modified version of the chemotherapeutic agent irinotecan, in which the drug is encapsulated in a nanoliposomal construct that is designed to improve delivery to the tumor and enhance anti-tumor efficacy while minimizing side effects in the rest of the body.
Click on the PDF icon at the top of this introduction to read the full article.